L
Labcyte
LabÂcyte Inc. is the maker of Echo® Acoustic Liquid Handling systems for life sciences
About Labcyte
Beckman Coulter Life Sciences, formerly known as Labcyte, specializes in providing advanced tools for optimizing research and manufacturing efficiency. The company offers a range of products including centrifuges, particle counters/analyzers, automated liquid handlers, and flow cytometers. These tools are designed to improve productivity for scientists, quality control experts, and other professionals. Beckman Coulter Life Sciences serves a diverse clientele, from prestigious universities and major pharmaceutical companies to small biotech startups and manufacturing facilities in the food, beverage, and electronics sectors. The business operates on a global scale, generating revenue through the sale of its specialized equipment and related services. By simplifying and automating complex biomedical testing, Beckman Coulter Life Sciences continues to make a significant impact in various industries.
Source: Dealroom company dataAt a glance
- Founded
- 2000
- Headquarters
- Sunnyvale, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- PIPalo Alto Investors
- AVAlloy Ventures
Sprout Group
Delphi Ventures
Series B and later6 investors entered at this stage
Cross Atlantic Capital Partners- CPCross Atlantic Partners
New Leaf Venture Partners
GE Ventures
Silicon Valley Bank
Oxford Finance
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Labcyte on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Labcyte on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.